NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) GSK. Those investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, extension 7980.

The investigation concerns whether GSK and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

On August 9, 2022, Vir Biotechnology, Inc. (“Vir”), GSK’s development partner for the proposed COVID-19 treatment sotrovimab, issued a press release disclosing that “Vir” and GSK do not intend to file a biologics license application sotrovimab and do not intend to proceed with the US-based Phase 3 COMET-STAR prophylaxis study. Discussions are ongoing with the FDA on the appropriate way forward for sotrovimab in the US.” On the news, GSK’s American Depositary Receipt fell $1.73 per share, or 4.32 percent, to close on March 10. August 2022 at $38.30 per share.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris and Tel Aviv, is recognized as one of the leading law firms specializing in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, best known as Dean of the Class Bar Association, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he founded and fights for the rights of victims of securities fraud, fiduciary breaches and corporate wrongdoing. The firm has recovered numerous multi-million dollar claims on behalf of group members. See www.pomlaw.com

CONTACT:
Robert S Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980